Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One-stage Clotting and Chromogenic Factor VIII Assay

Summary

In a study designed to demonstrate the safety and pharmacokinetics of a recombinant factor VIII (Recombinate) manufactured in Andover, MA and Thousand Oaks, CA, two different methods of factor VIII assay (one-stage clotting and Chromogenic substrate) were compared in vivo. The study was performed in four centres in the UK: London, Oxford, Cardiff and Manchester. Two pharmacokinetic studies, at least one week apart, were performed in 30 patients with severe haemophilia A (VIII:C < 2 IU/dl). A dose of 50 IU/kg was administered with sampling pre-infusion, and +0.25, 0.5, 1, 3, 6, 9, 12 and 24 h post-infusion. The aggregate 60 pharmacokinetic study showed a half-life of 12.7 and 13.0 h (p = 0.28) and recovery of 127 and 161 IU/dl (p = 0.0001) using one-stage clotting or chromogenic substrate respectively. In a supplementary experiment, 20 post-infusion samples were re-assayed by 1-stage and chromogenic assay using two plasma (20^th British plasma standard and an “in-house” pooled normal plasma) and two concentrate standards, derived from the same type, but different batch of infused concentrate (Recombinate) and pre-diluted in either individual pre-infusion sample or in pooled commercial haemophilic plasma. The use of the Recombinate concentrate standard overcame the significant difference in FVIII levels between 1-stage and chromogenic assay methods when a plasma standard was used (p <0.0001). It is concluded that where potency dosing designation is carried out by an assay system different to that used in the clinical situation, the use of the recombinant concentrate as a standard in post-infusion plasma samples is likely to give more reliable and reproducible results.

Keywords

Recombinant FVIII (Recombinate) - assay discrepancies

• References

• 1 Bray GL, Gomperts ED, Courter S. et al. A multicenter study of recombinant factor VIII (Recombinate): Safety efficacy and inhibitor risk in previously untreated patients with haemophilia A. Blood 1994; 83: 2428-35.
• 2 Lee C, Barrowcliffe T, Bray G. et al. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996; 76: 950-6.
• 3 Lee ML, Poon W-Y, Kingdon HS. A two-phase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115: 745-8.
• 4 Lusher JM, Wiseman C, Simpson P, Hurst P. Plasma levels measured after infusion of recombinant FVIII vary significantly with different assay methods – will the real FVIII level please stand up!. Blood 1995; 86 (Suppl. 01) 192a.
• 5 Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
• 6 Barrowcliffe TW. Comparisons of 1-stage and 2-stage assays of factor VIII:C. Scand J Haematol 1984; (33) (Suppl. 41) 39-54.
• 7 Barrowcliffe TW. The one-stage versus the two-stage factor VIII assay. In: Advances in Coagulation Testing. Triplett DA. ed. Skokie IL: College of American Pathologists; 1986: 47-62.
• 8 Hubbard AR, Curtis AD, Barrowcliffe TW, Edwards SJ, Jennings CA, Kemball-Cook G. Assay of factor VIII concentrates: comparison of chromogenic and 2-stage clotting assays. Thromb Res 1986; 44: 887-91.
• 9 Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 4: 634-40.
• 10 Nilsson IM, Blombäck M, Francken von I. On an inherited autosomal hemorrhagic diathesis with antihaemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35-7.
• 11 Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity – assay discrepancies. Haemophilia 1998; 4: 641-5.